Interleukin-36 receptor antagonist, active (IL36RN), Recombinant, Human

Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response, similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. May activate an anti-inflammatory signaling pathway by recruiting SIGIRR. {ECO:0000269, PubMed:11466363, ECO:0000269, PubMed:21965679, ECO:0000269, PubMed:23147407}. Biological Activity: Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0ug/ml, corresponding to a specific activity of ? 1000 IU/mg in the presence of 20ng/ml of recombinant human IL-36 beta. Sequence: VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD, Molecular Weight: 16.8kD, PubMed ID: 10625660, 10512743, 11093146, 11466363, 10860666, 11991722, 12975309, 14702039, 15815621, 15489334, 21965679, 23147407, 21839423, 21848462, 22903787, Gene Name: IL36RN,FIL1D,IL1F5,IL1HY1,IL1L1,IL1RP3,UNQ1896/PRO4342, Swiss Prot: Q9UBH0, Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.